抗コロナウイルス免疫グロブリン（ITAC）を用いたCOVID-19の入院治療

基本情報

NCT ID: NCT04546581
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 593
治験依頼者名: University of Minnesota

概要

This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo, when added to standard of care (SOC), for preventing further disease progression and mortality related to COVID-19. SOC will include remdesivir unless it is contraindicated for an individual patient.

対象疾患

COVIDCOVID-19SARS-CoV-2SARS (Severe Acute Respiratory Syndrome)

介入

Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)(BIOLOGICAL)

Placebo(OTHER)

Remdesivir(DRUG)

依頼者（Sponsor）

International Network For Strategic Initiatives In Global Hiv Trials (Insight)(NETWORK)

University Of Minnesota(OTHER)

National Institute Of Allergy And Infectious Diseases (Niaid)(NIH)

National Institutes Of Health (Nih)(NIH)

実施施設 (2)

藤田医科大学病院

Toyoake, Japan

NCGM

Tokyo, Japan